Drug Profile


Alternative Names: Tetravalent dengue virus purified inactivated vaccine with alum adjuvant

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer GlaxoSmithKline; United States Army Medical Research and Materiel Command; Walter Reed Army Institute of Research
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Dengue

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Dengue(Prevention) in Puerto Rico (IM, Injection)
  • 01 Aug 2015 Phase-I/II clinical trials in Dengue (Prevention) in USA (IM)
  • 15 Apr 2015 GlaxoSmithKline and Walter Reed Army Institute of Research plans a phase I/II trial for Dengue in USA (NCT02421367)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top